GP Andromix – Cut Mix

GP Andromix – Cut Mix Cutting Blend Overview

GP Andromix is an injectable pre-blended cutting compound from Geneza Pharmaceuticals containing three short-ester anabolic steroids at a combined concentration of 150 mg/ml in a 10 ml vial: Drostanolone Propionate, Testosterone Propionate, and Trenbolone Acetate at 50 mg/ml each. The blend is marketed under the brand name Cut Mix – a common designation for short-ester triple cutting blends in the injectable anabolic market. Commonly searched as Cut Mix, Cut Mix 150, Andromix, cut blend, and Geneza cut mix.

What Is GP Andromix?

GP Andromix combines the three most consistently referenced short-ester cutting compounds in a single injectable vial. Testosterone Propionate provides the mandatory testosterone base, Trenbolone Acetate contributes the primary anabolic and fat-loss cited effects, and Drostanolone Propionate (Masteron Propionate) adds DHT-derived hardening and anti-estrogenic properties. All three components use short esters (Propionate and Acetate) with half-lives of 2-3 days, requiring EOD injection schedules and allowing PCT to begin approximately 3-5 days after the last injection. The pre-blended format delivers all three compounds in a single injection, reducing the injection frequency compared to running each compound separately from individual vials.

Why Users Search for GP Andromix

Cut Mix blends are searched primarily for the injection convenience they provide – three compounds in one vial means one injection per EOD session rather than three. Community discussions of GP Andromix center on the convenience advantage versus the dosing inflexibility trade-off: individual component doses are fixed at 50 mg/ml each in the blend and cannot be adjusted independently. Users who want different ratios of Testosterone Propionate, Trenbolone Acetate, and Drostanolone Propionate are directed toward individual vials of each compound. GP Andromix is compared to running the same three compounds separately: the individual Geneza equivalents are GP Test Prop 100, GP Tren Acetate 100, and GP Mast 100.

• Active substances: Drostanolone Propionate + Testosterone Propionate + Trenbolone Acetate – 50 mg/ml each, 150 mg/ml combined.
• Concentration: 150 mg/ml in a 10 ml vial – 1500 mg total combined anabolic content (500 mg per compound).
• Injection schedule: EOD – all three components use Propionate or Acetate esters with 2-3 day half-lives.
• Common names: Cut Mix, Cut Mix 150, Andromix, cut blend, short-ester cutting blend, Geneza cut mix.
• Cycle context: Cutting, pre-competition, lean mass; short-ester triple blend convenience versus individual compound flexibility.

GP Andromix Dose and Concentration Information

GP Andromix is listed at 150 mg/ml combined concentration. A 10 ml vial contains 1500 mg total anabolic content – 500 mg Drostanolone Propionate, 500 mg Testosterone Propionate, and 500 mg Trenbolone Acetate. All three components use short esters (Propionate or Acetate) with half-lives of approximately 2-3 days, requiring EOD injections for stable blood levels across all three compounds simultaneously.

Blend Concentration and Ester Context

The 50 mg/ml per compound ratio in GP Andromix is fixed – each injection delivers equal amounts of all three components. This is the primary dosing consideration discussed in community references for pre-blended triple compounds: the ratio of Testosterone Propionate to Trenbolone Acetate to Drostanolone Propionate cannot be adjusted without adding individual compound vials alongside the blend. EOD injection schedule applies to the whole blend simultaneously, allowing PCT to begin approximately 3-5 days after the last Andromix injection – consistent with the Propionate and Acetate ester clearance profile and significantly earlier than long-ester Enanthate-based cutting compounds.

Bloodwork and Monitoring Context

GP Andromix contains Testosterone Propionate, which aromatizes to estrogen – estrogen monitoring and aromatase inhibitor use are referenced for the blend despite Trenbolone Acetate and Drostanolone Propionate not aromatizing. Trenbolone Acetate’s progestogenic activity means prolactin monitoring is a relevant consideration alongside estrogen. Cardiovascular monitoring (blood pressure, hematocrit, lipid panel) applies to all three components. HPTA suppression is complete from both the testosterone and Trenbolone components – a PCT protocol after cycle is mandatory. Liver markers are referenced in the context of Trenbolone’s known impact on lipids rather than hepatotoxicity.

• Concentration: 150 mg/ml combined – 50 mg/ml Drostanolone Propionate + 50 mg/ml Testosterone Propionate + 50 mg/ml Trenbolone Acetate.
• Total content: 1500 mg combined per 10 ml vial (500 mg per compound).
• Injection schedule: EOD – Propionate and Acetate esters with approximately 2-3 day half-lives across all three components.
• PCT timing: Approximately 3-5 days post-last-injection – short ester clearance consistent with individual Propionate/Acetate compounds.
• Estrogen monitoring: Required – Testosterone Propionate aromatizes; AI referenced for estrogen management from the testosterone component.
• Prolactin monitoring: Referenced – Trenbolone Acetate has progestogenic activity; Cabergoline cited for prolactin management.
• Cardiovascular: Blood pressure, hematocrit, lipid panel – standard monitoring for Trenbolone-containing cycles.